4381. Probiotics in COVID-19 pandemic: when evidence lacks, rationale can still ease the way.
作者: Cristiano Pagnini.;Maria Carla DI Paolo.;Lucia D'Alba.;Riccardo Urgesi.;Lorella Pallotta.;Giuseppe Villotti.;Giancarlo D'Ambra.;Gianfranco Delle Fave.;Maria Giovanna Graziani.
来源: Minerva Gastroenterol (Torino). 2023年69卷2期314-317页 4382. Fibromax and inflamatory markers cannot replace liver biopsy in the evaluation of non-alcoholic fatty liver disease.
作者: Leonardo L Lardi.;Rodrigo M Lul.;Gabriela Z Port.;Gabriela P Coral.;Alessandra Peres.;Gilson P Dornelles.;Fernanda Branco.;Sabrina Fernandes.;Carolina G Leães.;Angelo A Mattos.;Caroline Buss.;Cristiane V Tovo.
来源: Minerva Gastroenterol (Torino). 2022年68卷1期85-90页
To evaluate the performance of a non-invasive test (Fibromax™, Ferring Pharmaceutical, Saint-Prex, Switzerland) and inflamatory markers (IL-1β, IL-6, IL-8, TNF-α, MCP-1) in the diagnosis and staging of patients with non-alcoholic fatty liver disease.
4387. Non-cirrhotic portal hypertension in inflammatory bowel disease.
With the increasing incidence and prevalence of inflammatory bowel diseases (IBD), its complications and associated morbidity also continue to rise. One of these is non-cirrhotic portal hypertension. There is an increasing need of recognizing and understanding the pathophysiology of this condition in the clinical setting of IBD, especially in long standing cases. Due to multiple potential factors, patients with IBD appear to be at a higher risk of developing portal hypertension even in the absence of liver cirrhosis. Portal hypertension is usually diagnosed when complications (such as ascites, variceal bleeding) develop, especially when patients have already experienced multiple complications of the disease. Hence, a high level of vigilance for the detection of portal hypertension at an early stage is needed. This review discusses the known epidemiology, clinical characteristics, clinical presentation, modalities of diagnosis and the potential treatments of the different forms of non-cirrhotic portal hypertension associated with IBD. The concomitant presence of portal hypertension can significantly impact the overall clinical picture and disease burden in IBD. Hence, increased awareness of this condition at an early stage might help tailor a comprehensive and individualized therapeutic plan of care for these patients.
4391. Something new in the management of acute pancreatitis: brief review of recent guidelines and practical tips.
作者: Giovanni Valentini.;Monica Surace.;Immacolata Andria.;Dario Mazzucco.
来源: Minerva Gastroenterol (Torino). 2023年69卷2期300-311页
Improvement in diagnostic and therapeutic techniques has led to revision of past guidelines on the management of acute pancreatitis (AP), still not uniformly applied on the territory, partly due to the different distribution of resources to the various centers, partly due to the lack of unequivocal conduct in the approach itself. We had tried to outline most important changes emerged from the revision of recent and authoritative guidelines, focusing on what we believe are still critical points and identifying attitudes more equally shared than others. Based also on the experience of our small center, which however manages numerous cases of AP and their complications, we finally proposed a simple decision algorithm, which does not claim to be a codified recommendation, but only a small and concrete suggestion.
4394. Efficacy of artichoke and ginger extracts with simethicone to treat gastrointestinal symptoms in endurance athletes: a pilot study.
作者: Franchek Drobnic.;Sergi Fonts.;Iker García-Alday.;Giovanna Petrangolini.;Antonella Riva.;Elisabetta Frattini.;Pietro Allegrini.;Stefano Togni.;Jacopo Vitale.
来源: Minerva Gastroenterol (Torino). 2022年68卷1期77-84页
Exercise-induced gastrointestinal (GI) symptoms are frequently reported by athletes during training and competitions. A standardized combination of artichoke leaves and ginger root extracts has shown beneficial effects in managing GI discomfort in otherwise healthy subjects.
|